# Present and Past of Nuclear Medicine in ATTR Cardiac Amyloidosis Imaging

Annual Meeting of the Working Group on Myocardial & Pericardial Diseases

Dr. Shay Livschitz
Nuclear Cardiology Unit, Kaplan Medical Center

#### Disclosures for Dr. Shay Livschitz

| Research Support            | Spectrum Dynamics Medical |
|-----------------------------|---------------------------|
| Employee                    | Kaplan MC                 |
| Consultant and/or Honoraria | Pfizer                    |
| Stockholder                 |                           |
| Scientific Advisory Board   |                           |

# ATTR Cardiac Amyloidosis Underdiagnosis "Revolution"


- Noninvasive diagnostic tools have a limited value in the diagnosis and type identification of CA.
- Fat pad biopsy though simple, has low diagnostic yield in ATTR cardiac amyloidosis (sensitivity: 15% in wildtype ATTR, 45% in mutan ATTR).
- This is why historically, endomyocardial biopsy has been used to confirm cardiac amyloidosis and identify the fibril type.
- Recently, *nuclear medicine cardiac imaging* has revolutionized the field's ability to specifically diagnose ATTR cardiac amyloidosis noninvasively, obviating the need for endomyocardial biopsy.

Julian D. Gillmore, MD, PhD; Mathew S. Maurer, MD; Rodney H. Falk, MD;

(Circulation. 2016;133:2404-2412)

- Multicenter collaboration studied 1,217 patients referred for suspicion of CA who underwent cardiac scintigraphy with 99mTc-pyrophosphate [99mTc-PYP], 99mTc-3,3-diphosphono1,2-propanodicarboxylic acid [99mTc-DPD], and or with 99mTc-hydroxymethylene diphosphonate [99mTcHMDP]).
- According to the grading devised by Perugini 99mTc-PYP:

grade 0=absent cardiac uptake; grade 1=mild uptake less than bone grade 2=moderate uptake equal to bone grade 3=high uptake greater than bone



Julian D. Gillmore, MD, PhD; Mathew S. Maurer, MD; Rodney H. Falk, MD;

#### Radionuclide 'Bone' Scintigraphy Findings Among 374 Patients With EMBs

|  | <u> </u>                   |             |               |            |     |
|--|----------------------------|-------------|---------------|------------|-----|
|  | 99mTc-DPD Scan Findings, n |             |               |            |     |
| EMB Findings                             | Perugini 0                 | Perugini 1  | Perugini 2    | Perugini 3 | n   |
| No cardiac amyloid                       | 31                         | 3           | 0             | 1          | 35  |
| Cardiac ATTR amyloid deposits            | 1                          | 8           | 130           | 23         | 162 |
| Cardiac AL amyloid deposits              | 21                         | 13          | 7             | 2          | 43  |
| Cardiac ApoAl amyloid deposits           | 0                          | 2           | 0             | 0          | 2   |
| Cardiac amyloid deposits of unknown type | 1                          | 1           | 0             | 0          | 2   |
| Total                                    | 54                         | 27          | 137           | 26         | 244 |
|  |                            | 99mTc-PYP S | Scan Findings |            |     |
|  | Grade 0                    | Grade 1     | Grade 2       | Grade 3    | n   |
| No cardiac amyloid                       | 7                          | 1           | 1             | 0          | 9   |
| Cardiac ATTR amyloid                     | 1                          | 10          | 7             | 67         | 85  |
| Cardiac AL amyloid deposits              | 10                         | 1           | 3             | 1          | 15  |
| Cardiac ApoAl amyloid deposits           | 0                          | 0           | 0             | 0          | 0   |
| Cardiac amyloid deposits of unknown type | 0                          | 0           | 0             | 0          | 0   |
| Total                                    | 18                         | 12          | 11            | 68         | 109 |
|  | 99mTc-HMDP Scan Findings   |             |               |            |     |
|  | Grade 0                    | Grade 1     | Grade 2       | Grade 3    | n   |
| No cardiac amyloid                       | 3                          | 0           | 0             | 0          | 3   |
| Cardiac ATTR amyloid deposits            | 0                          | 3           | 4             | 7          | 14  |
| Cardiac AL amyloid deposits              | 4                          | 0           | 0             | 0          | 4   |
| Cardiac ApoAl amyloid deposits           | 0                          | 0           | 0             | 0          | 0   |
| Cardiac amyloid deposits of unknown type | 0                          | 0           | 0             | 0          | 0   |
| Total                                    | 7                          | 3           | 4             | 7          | 21  |

Julian D. Gillmore, MD, PhD; Mathew S. Maurer, MD; Rodney H. Falk, MD;

(Circulation. 2016;133:2404-2412)

|                                  | Positive Scan (Grade 1, 2, or 3), n | Negative Scan (Grade 0), n |                        |
|----------------------------------|-------------------------------------|----------------------------|------------------------|
| Cardiac ATTR amyloid deposits    | 259                                 | 2                          | >99 (97–100) sensitive |
| No cardiac ATTR amyloid deposits | 36                                  | 77                         | 68 (59–77) specific    |

• The low specificity (68%) of a positive scan (grades 1-3) for cardiac ATTR amyloid deposits was due almost entirely to cardiac uptake of tracer among patients with cardiac AL or cardiac apolipoprotein A-I amyloidosis.

|                                  | Grade 2/3 Scan, n | Grade 0/1 Scan, n |                      |
|----------------------------------|-------------------|-------------------|----------------------|
| Cardiac ATTR amyloid deposits    | 238               | 23                | 91 (87–94) sensitive |
| No cardiac ATTR amyloid deposits | 15                | 98                | 87 (79–92) specific  |

- The specificity for cardiac ATTR amyloid of grade 2 or 3 cardiac uptake on radionuclide imaging increases to ≈87%, but the sensitivity falls to 91%
- The specificity and positive predictive value for cardiac ATTR amyloid of the combination of **grade 2 or 3 cardiac** uptake on a radionuclide scan and the **absence of a detectable monoclonal protein** were 100% (positive predictive value confidence interval, 99.0–100%) in this cohort of 1217 patients and were also 100% among each of the 3 different radiotracer cohorts

- "Cardiac ATTR amyloidosis can be reliably diagnosed in the absence of histology provided that all of the following criteria are met:
- heart failure with an echocardiogram or CMR that is consistent with or suggestive of amyloidosis,
- grade 2 or 3 cardiac uptake on a radionuclide scan with 99mTc-DPD, 99mTcPYP, or 99mTc-HMDP,
- absence of a detectable monoclonal protein"
- The *high test performance* characteristics were favorably skewed owing to the high pre-test likelihood in the study cohort.


## Nonbiopsy Diagnosis of Transthyretin Cardiac Amyloidosis

• Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered.

• These early studies showed "high-diagnostic accuracies" leading to great excitement in the


field and a profusion of studies.


| First<br>Author                  | Radiotracer           | N     | Cohort  | Prevalence<br>of ATTR |
|----------------------------------|-----------------------|-------|---|-----------------------|
| Gonzalez-<br>Lopez <sup>38</sup> | <sup>99m</sup> Tc-DPD | 120   | Heart failure with preserved EF<br>Hospitalized patients<br>42% women   | 13.3%                 |
| Castano <sup>39</sup>            | <sup>99m</sup> Tc-PYP | 151   | TAVR Age > 75 years Severe aortic stenosis  | 16%                   |
| Haq <sup>36</sup>                | <sup>99m</sup> Tc-PYP |       | Low flow low gradient AS Mean LVEF 46% Hereditary ATTR No heart failure   | 83%                   |
| Bennani-<br>Smires <sup>37</sup> | <sup>99m</sup> Tc-DPD | 49    | Normal echocardiogram  Normal cardiac biomarkers  Age > 65 years  Heart failure with preserved EF   | 18%                   |
| Longhi S <sup>56</sup>           | <sup>99m</sup> Tc-DPD | 43    | Aortic stenosis 5 with echo red flags underwent <sup>99m</sup> Tc-DPD and all were strongly positive  | 11.6%                 |
| Longhi S <sup>41</sup>           | 99mTc-DPD             | 12400 | All bone scans performed over a $5 + year$ period for clinical reasons  | 0.36%                 |
| Mohamed-<br>Salem <sup>42</sup>  | 99mTc-DPD             | 1114  | Age ≥ 75 years<br>Bone scan for clinical reasons  | 2.78%                 |
| Sperry <sup>40</sup>             | <sup>99m</sup> Tc-PYP | 98    | Carpal tunnel surgery Men ≥ 50 years Women ≥ 60 years 10 patients with biopsy proven amyloid from carpal tunnel procedure were evaluated by <sup>99m</sup> Tc-PYP | 10.2%                 |



Patient History:
Male, 60Y
NIDDM
HTN
CLBBB
Dilated CMP

True or false positive TTR-CA? Where the uptake is?







Tshori S, Livschitz S, Volodarsky I, Goland S, Shimoni S, Fabrikant J, George J J Nucl Cardiol. 2021 Transthyretin Cardiac Amyloidosis Scintigraphy Using Planar D-SPECT on Dedicated Cardiac CZT Camera

#### Anger Planar


#### **D-SPECT Planar**





Patient History: Male, 80Y
Indication: hypertension,
hypercholesterolemia
S/P CABG + AVR
Chronic atrial fibrillation
Heart failure with systolic dysfunction
(EF 35%)
NYHA III


## TTR Cardiac Amyloidosis PYP Tc-99m scan – D-SPECT




Patient History: Male,73Y

Indication: hypertension, hyperlipidemia, carpal tunnel syndrome

Findings: Positive TTR
Acquisition time: 10 min
Injected Dose: 20Mci




## TTR Cardiac Amyloidosis PYP Tc-99m scan – D-SPECT




Patient History: Male, 44Y


**Indication:** Multiple sclerosis, numbness

Findings: Negative TTR
Acquisition time: 10 min
Injected Dose: 20Mci



#### TTR Cardiac Amyloidosis Positive – SPECT PYP Tc-99m scan





Patient History: Male, 75Y

**Indication:** hypertension, hypercholesterolemia, CVA

Heart failure without systolic dysfunction (EF 55%)

Suspected restrictive CMP at echo

Moderate to severe MR


Severe PHT


**Acquisition time:** 5 min **Injected Dose:** 20 Mci


# PYP Tc-99m SPECT Gated Imaging

**Blood Pool Imaging** 

TTR Cardiac Amyloidosis








Patient History:
Male, 60Y
NIDDM
HTN
CLBBB
Dilated CMP

True or false positive TTR-CA? Where the uptake is?

### TTR Cardiac Amyloidosis – Gated SPECT PYP Tc-99m scan



Patient History: Male, 60Y


**NIDDM** 

HTN


**CLBBB** 

**Dilated CMP** 

Acquisition time: 10 min Injected Dose: 20 Mci



**Blood Pool Imaging** 



Patient History:
Male, 60Y
NIDDM
HTN
CLBBB
Dilated CMP

True or false positive TTR-CA? False
Where the uptake is? Blood pool

Planar imaging alone is limited as myocardial uptake cannot be discerned from blood pool uptake, overlying rib uptake may add counts to the region of the heart.


# Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate

Poterucha et al .JACC: CARDIOVASCULAR IMAGING, VOL. 14, NO. 6, 2021

- A total of 753 unique patients underwent 99mTc-PYP scanning at Columbia University Irving Medical Center were included in this study.
- Standardized imaging protocol with 99mTc-PYP imaged at 1 h after injection

|  | Total Patients (N = 753) |                       | Vithout Cardiac<br>/ (n = 649) |                     | With Cardiac<br>y (n = 104) |
|--|--------------------------|-----------------------|--------------------------------|---------------------|-----------------------------|
|  | Total                    | ATTR-CA*<br>(n = 127) | No Amyloidosis<br>(n = 434)    | ATTR-CA<br>(n = 69) | No Amyloidosis<br>(n = 22)  |
| Age, yrs                                     | 76.7 ± 10.9              | 79.4 ± 8.4            | 76.8 ± 11.4                    | 72.9 ± 8.5          | 69.9 ± 8.3                  |
| Male   | 513 (68)                 | 96 (76)               | 264 (61)                       | 59 (86)             | 17 (77)                     |
| Racial/ethnic background                     |                          |                       |                                |                     |                             |
| White  | 537 (71)                 | 86 (68)               | 321 (74)                       | 48 (70)             | 15 (68)                     |
| Black  | 106 (14)                 | 22 (17)               | 58 (13)                        | 10 (14)             | 5 (23)                      |
| Hispanic                                     | 49 (7)                   | 5 (4)                 | 27 (6)                         | 5 (7)               | 1 (5)                       |
| Other/unknown                                | 61 (8)                   | 15 (12)               | 28 (6)                         | 6 (9)               | 1 (5)                       |
| Echocardiography                             |                          |                       |                                |                     |                             |
| LV ejection fraction, % (n = 693)            | 55 (38-60)               | 47 (35-56)            | 55 (43-63)                     | 46 (31-57)          | 50 (30-60)                  |
| IVS, mm (n = 736)                            | 13 (11-15)               | 15 (13-18)            | 12 (10-13)                     | 16 (15-19)          | 11 (10-14)                  |
| LVPWT, mm (n = 735)                          | 12 (10-14)               | 15 (13-16)            | 11 (9-12)                      | 16 (14-18)          | 10 (9-13)                   |
| Left atrial volume index, $ml/m^2$ (n = 556) | 50 (40-63)               | 51 (43-62)            | 50 (39-65)                     | 46 (41-52)          | 51 (46-78)                  |
| PYP visual score                             |                          |                       |                                |                     |                             |
| Grade O                                      | 307 (41)                 | 2* (1)                | 278 (64)                       | 0 (0)               | 12 (55)                     |
| Grade 1                                      | 177 (24)                 | 1* (1)                | 153 (35)                       | 4 (6)               | 7 (32)                      |
| Grade 2                                      | 37 (5)                   | 5 (3)                 | 3 (1)                          | 2 (3)               | 3 (14)                      |
| Grade 3                                      | 232 (31)                 | 119 (94)              | 0 (0)                          | 63 (91)             | 0 (0)                       |
| PYP H:CL (n = 751)                           |                          |                       |                                |                     |                             |
| <1.5   | 502 (67)                 | 5 (4)                 | 430 (100)                      | 3 (4)               | 21 (95)                     |
| ≥1.5   | 249 (33)                 | 122 (96)              | 2 (0)                          | 66 (96)             | 1 (5)                       |


# SPECT Results As Function Of Planar Visual Grading Score Patients Undergoing 99mtc-pyp Scanning



| Grade | Planar visual score<br>n=257 patients | SPECT +<br>Myocardial uptake |
|-------|---------------------------------------|------------------------------|
| 0     | 72                                    | 0                            |
| 1     | 81                                    | 0                            |
| 2     | 25                                    | 9(36%)                       |
| 3     | 79                                    | 79 (100%)                    |

# Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate

Poterucha et al .JACC: CARDIOVASCULAR IMAGING, VOL. 14, NO. 6, 2021



99mTc-PYP scanning that is visual score grade 2 with planar imaging alone is often a false positive result

# Non-ATTR Causes of Positive Technetium-Labeled Cardiac Scintigraphy

#### **False positive**

- Blood pool
- Rib fractures that may overlay the heart, thereby raising radiotracer counts (affecting H/CL ratio calculation) or mimicking myocardial uptake.
- Acute or subacute myocardial infarction can lead to focal uptake.
- Rare forms of CA: hereditary apolipoprotein A1.

#### **False negative**

- TTR mutations: Phe64Leu and Val30Met, have been noted to have typical cardiac involvement by echocardiography but negative cardiac scintigraphy results.
- Myocardial infiltration is minimal, as in early stage disease, thus causing uptake to be below the current diagnostic detection threshold.
- Delayed or premature acquisition.

# TTR Cardiac Amyloidosis <sup>99m</sup>Tc-PYP Imaging in 2022 Everyday Practice

**Grading 99mTc-PYP Uptake on Planar an SPECT Images Not suggestive** Equivocal Strongly suggestive **Planar Planar SPECT SPECT GATED GATED** Grade 0 Grade 2 Grade 3 Grade 1 H/Cl ratio <1 H/Cl ratio <1-1.5 H/Cl ratio >1.5

Early enthusiasm based upon data from highly selected referral populations is being tempered by the recognition of diminished accuracy that has been observed with widespread clinical application.

• As cardiac scintigraphy is increasingly used in screening populations with minimal increase in left ventricular wall thickness, we suspect that testing results are going to be less favorable with high false positive rates.

• Recognition that a single test alone does not establish or exclude the diagnosis of ATTR-CM is central to the proper application of 99mTc-PYP, 99mTcDPD, 99mTc-HMDP scintigraphy in the appropriate clinical context.

## ATTR Cardiac Amyloidosis Imaging at the Present Time

The combination of:

careful case selection for cardiac scintigraphy,

appropriate scanning protocols,

confirmation of all positive planar imaging by SPECT,


may help to mitigate this and maintain diagnostic accuracy in the work-up of suspected ATTR-CA.

• Early and accurate diagnosis of ATTR cardiac amyloidosis makes possible targeted therapy with novel disease-modifying agents to substantially reduce heart failure hospitalization and improve survival.





# Thank you bor your attention



Patient History:
Male, 60Y
NIDDM
HTN
CLBBB
Dilated CMP

True or false positive TTR-CA? Where the uptake is?

Planar imaging alone is limited as myocardial uptake cannot be discerned from blood pool uptake, overlying rib uptake may add counts to the region of the heart.